 Home > Biochemistry News > Biotechnology News > Results of key clinical trials of TCR cell therapy actively support the submission of regulatory applications next year

Results of key clinical trials of TCR cell therapy actively support the submission of regulatory applications next year

 Last Update: 2021-12-02
 Source: Internet
 Author: User

Tags

testolone results

product data sheet

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Adaptimmune Therapeutics announced that its T cell therapy afamitresgene autoleucel (afami-cel, formerly ADP-A2M4), which targets the MAGE-A4 antigen, is used in the treatment of advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) Positive results were obtained in the pivotal phase 2 clinical trial

Adaptimmune's TCR-T cell therapy platform is called SPEAR (Specific Peptide Enhanced Affinity Receptor)

Adaptimmune's technology platform first identifies the antigen fragments displayed by cancer cells' unique HLA, and then screens out TCRs that bind to this antigen fragment and further genetically engineer them to enhance the affinity of TCR and antigen fragments, thereby increasing the TCR Activation of cells

▲Adaptimmune's engineered TCR-T cell therapy (picture source: Adaptimmune official website)

In this trial, 47 patients who had undergone a variety of pre-treatments received afami-cel treatment and the efficacy could be evaluated

In terms of safety, 66% of patients have cytokine release syndrome, most of which are grade 1 or 2

Reference materials:

[1] Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.